New Delhi, March 23 -- Just as cheaper weight-loss drugs were set to flood the market, India's drug regulator has stepped in with a warning shot.

The Drugs Controller General of India has asked states to ensure that only endocrinologists prescribe semaglutide, a powerful diabetes drug now widely used for weight loss, following raids on wellness centres where unqualified practitioners were dispensing it.

The move comes days after Novo Nordisk's patent expired, triggering a rush of low-cost versions from major Indian drugmakers. While this could cut treatment costs by 50-70% and expand access, regulators fear misuse as demand surges beyond diabetes patients to those seeking quick weight loss.

Experts say the concerns are real. The drug c...